On November 22, 2023, Femasys Inc. closed the transaction. The company received $1,850,000 in its second and final tranche. The company received funding pursuant to Regulation D in the transaction from 4 investors.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.31 USD | -0.76% | 0.00% | +36.41% |
Apr. 01 | HC Wainwright Adjusts Femasys' Price Target to $12 From $10, Reiterates Buy Rating | MT |
Mar. 28 | Femasys Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
2.12 USD | +0.47% | -4.50% | 17.92M | ||
1.31 USD | -0.76% | 0.00% | 29.17M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+36.41% | 29.17M | |
-3.41% | 186B | |
-2.90% | 107B | |
-4.34% | 67.44B | |
+1.86% | 50.03B | |
+16.67% | 47.81B | |
+4.79% | 41.03B | |
+2.54% | 26.85B | |
+0.28% | 25.82B | |
-0.58% | 25.01B |
- Stock Market
- Equities
- FEMY Stock
- News Femasys Inc.
- Femasys Inc. announced that it has received $6.85 million in funding from PharmaCyte Biotech, Inc. and other investors